101 related articles for article (PubMed ID: 2291460)
21. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Nabholtz JM; Mackey JR; Smylie M; Paterson A; Noël DR; Al-Tweigeri T; Tonkin K; North S; Azli N; Riva A
J Clin Oncol; 2001 Jan; 19(2):314-21. PubMed ID: 11208821
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
23. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil.
Li JJ; Di GH; Tang LC; Yu KD; Hu Z; Liu GY; Lu JS; Wu J; Han QX; Shen ZZ; Shao ZM
Breast J; 2011; 17(6):657-60. PubMed ID: 21933300
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
Ransom DT; Neuberg D; Loprinzi CL; Tormey DC; Blum RH; Harris JE; Asbury RF; Falkson G
Am J Clin Oncol; 1991 Feb; 14(1):45-8. PubMed ID: 1898999
[TBL] [Abstract][Full Text] [Related]
26. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy with cis-platin, doxorubicin, and cyclophosphamide (CAP) in patients with metastatic breast cancer.
Colozza M; Gori S; Mosconi AM; Belsanti V; Basurto C; Rossetti R; Di Costanzo F; Buzzi F; Bacchi M; Davis S
Am J Clin Oncol; 1989 Apr; 12(2):137-41. PubMed ID: 2705403
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
Hortobagyi GN; Bodey GP; Buzdar AU; Frye D; Legha SS; Malik R; Smith TL; Blumenschein GR; Yap HY; Rodriguez V
J Clin Oncol; 1987 Mar; 5(3):354-64. PubMed ID: 3819804
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of pirarubicin in metastatic breast cancer.
Kleeberg UR; Reichel L; Wander HE; Beyer JH; Essers U; Fiebig HH; Salewski E; Greifenberg B; Edler L
Onkologie; 1990 Jun; 13(3):175-9. PubMed ID: 2204003
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Valero V; Buzdar AU; Theriault RL; Azarnia N; Fonseca GA; Willey J; Ewer M; Walters RS; Mackay B; Podoloff D; Booser D; Lee LW; Hortobagyi GN
J Clin Oncol; 1999 May; 17(5):1425-34. PubMed ID: 10334527
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
; ; . PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
